Backs FY25 total revenue view up high single-digit percentage. The company said, “AstraZeneca (AZN) reiterates its Total Revenue and Core EPS guidance4 for FY 2025 at CER, based on the average foreign exchange rates through 2024.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca: Strong Financial Performance and Promising Pipeline Support Buy Rating
- AstraZeneca reports Q3 core EPS $2.38, up 12% at CER
- AstraZeneca sees FY25 core EPS increasing by low double-digit percentage
- These Are the Stocks Reporting Earnings Today – November 6, 2025
- AZN Earnings Report this Week: Is It a Buy, Ahead of Earnings?